Natixis cut its stake in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 26.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 115,933 shares of the medical research company’s stock after selling 40,643 shares during the period. Natixis’ holdings in […]
Brown Advisory Inc. raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,341,102 shares of the medical research company’s stock after acquiring an additional 115,268 […]
Ossiam lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,475 shares of the medical research company’s stock after selling 1,374 shares during the period. Ossiam’s holdings […]
Morgan Stanley initiated coverage on shares of Edwards Lifesciences (NYSE:EW – Get Rating) in a research report sent to investors on Tuesday, FinViz reports. The firm issued an overweight rating and a $102.00 price target on the medical research company’s stock. Several other brokerages have also commented on EW. Wells Fargo & Company boosted their […]
Research analysts at Morgan Stanley started coverage on shares of Edwards Lifesciences (NYSE:EW – Get Rating) in a research note issued to investors on Tuesday, FinViz reports. The brokerage set an “overweight” rating and a $102.00 price target on the medical research company’s stock. Morgan Stanley’s price target suggests a potential upside of 19.69% from […]